Nci a549

Cell lines used in this study, which included lines derived from hepatocellular carcinoma cells (HpG2), lung cancer cells (NCI-A549, hereafter referred to as A549 cells; NCI-H1299, hereafter referred to as H1299 cells), breast cancer cells (MCF-7), colorectal cancer cells (HCT-8), and pancreatic cancer cells (PANC-1), were obtained from KeyGen Biotech (Nanjing, China). All cells were cultured in RPMI 1640 or DMEM media supplemented with 10% fetal bovine serum under conditions of 37°C, 95% humidity, and 5% CO₂ (hereafter referred to as standard cell culture conditions). No primary human tumor specimens were used in this study.

The following human cell lines were obtained from KeyGen Biotech (Nanjing, China): liver (PLC/PRF/5), lung (NCI-A549), breast (MCF-7), and colon (HCT-8) cancer cell lines. The cells were grown in 1640 medium supplemented with 10% fetal bovine serum (Hyclone, USA) and maintained at 37 °C with 5% CO₂ in a humidified atmosphere. The liver (HepG2) and pancreatic (PANC-1) cancer cell lines were cultured in DMEM medium supplemented with 10% fetal bovine serum (Hyclone, USA) and maintained at 37 °C with 5% CO₂ in a humidified atmosphere. The siRNA of STAT3 was obtained from GenePharma Technology (Shanghai, China). The siRNAs of STAT3 and siRNA control vector were transfected into PLC/PRF/5 and HepG2 cells with Lipofectamine 2000 (Invitrogen, USA).